Digital Public Defence Apr. 26, 2021 12:15 Maxi-Lu Böschen

Kranjec C, Eilertsen IA, Nunes L, Moosavi SH, Berg KCG, Eknæs M, Hektoen M, Niederdorfer B, Lind GE, Skotheim RI, Sveen A, Lothe RA (2026)
Common gene mutations in 103 authenticated colorectal cancer cell lines
Oncogenesis (in press)
DOI 10.1038/s41389-026-00599-0, PubMed 41593049

Svalheim KG, Andresen NK, Bjerre C, Gilje B, Jakobsen EH, Falk RS, Naume B, Kaasa S, Kyte JA (2026)
Patient-reported outcomes from the randomized ALICE trial evaluating the addition of atezolizumab to anthracycline-based chemotherapy in metastatic triple-negative breast cancer
Breast, 86, 104704 (in press)
DOI 10.1016/j.breast.2026.104704, PubMed 41581361

Landsverk HB, Sandquist LE, Bay LTE, Hauge S, van Bijsterveldt L, Lindbergsengen L, Lund-Andersen C, Kanduri C, Lyng H, Fjeldbo CS, Hompland T, Humphrey TC, Syljuåsen RG (2026)
Transcription termination counteracts DNA damage after WEE1 inhibition
Nucleic Acids Res, 54 (3)
DOI 10.1093/nar/gkaf1487, PubMed 41569153

Slørdahl KS, Puco K, Falk RS, Dyvik I, Brabrand S, Niehusmann P, Steinskog ESS, Blix ES, Flobak Å, Oppedal IA, Meltzer S, Torkildsen CF, Blakstad H, Lindemann K, Smeland S, Amundsen A, Taskén K, Helland Å, InPred Consortium (2026)
Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial
Acta Oncol, 65, 90-96
DOI 10.2340/1651-226X.2026.45086, PubMed 41664938

Davidson B, Stričak LM, Holth A, Torgunrud A, Wohlschlaeger J, Tötsch M, Bassarova A (2026)
The specificity of HEG1 as mesothelioma marker depends on the differential diagnosis
Virchows Arch (in press)
DOI 10.1007/s00428-026-04438-w, PubMed 41656400

Thorgersen EB, Dagenborg VJ, Schultz JK (2026)
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies: How, to whom, and is centralization needed?
Scand J Surg, 14574969261418796 (in press)
DOI 10.1177/14574969261418796, PubMed 41655138